You and other boosters on here bang on about how long it takes...

You and other boosters on here bang on about how long it takes to commercialise a new treatment, I get that. I have some limited experience of FDA approval processes.

Now let me ask you a couple of simple questions and please try not to dodge them.

1. What percentage of MSB shareholders from 2008 do you estimate seriously thought they'd still be waiting for profitability in March 2018?
2. Do you believe that those who bought in at over $8 and $9 during 2011 would have done so if they had have known that profitability (or even a commercial partner to pay for the completion of their trials) would still be an incomplete objective as far out as 2018?

I like some aspects of the company but from my (albeit limited) perspective but (and it is just my view) some elements of their past commercial execution appear terrible and you appear to want to refuse to accept statement of some basic facts around past share price performance without sundry accusations of malice.

I come here to try and view the comments of others having a debate about these issues and the possibility of the company succeeding to strong profitability (yes, possibility, even the company reports acknowledge risks) but it's very difficult when you and others keep banging on incessantly about shorters in the most general (and ultimately futile) manner.

You've made your point, can you let it go. Tell us all, when do you think they'll be profitable?